Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Quick Read Ionis Pharmaceuticals (IONS) trades at $72.70 with Barclays raising its price target to $106, citing a projected $4 billion peak sales opportunity for olezarsen in severe hypertriglyceridemia with a June 30, 2026 PDUFA date, while Tryngolza generated $108 million in 2025 sales with Q4 revenue of $50 million demonstrating strong launch momentum. Ionis must achieve regulatory approval for olezarsen and demonstrate early commercial upt…

Barclays Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $106.00

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its target price hoisted by analysts at Barclays from $95.00 to $106.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price points to a potential upside of 47.40% from the stock’s previous close. IONS has […]